Trial Profile
Phase I Study of IMC-A12 (NSC 742460) in Combination With Temsirolimus CCI-779 (NSC# 683864) in Patients With Advanced Cancers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Cixutumumab (Primary) ; Temsirolimus (Primary)
- Indications Cancer
- Focus Adverse reactions; Biomarker; Therapeutic Use
- 03 Nov 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 03 Nov 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 15 Jun 2012 Planned end date changed from 1 May 2014 to 1 Jun 2013 as reported by ClinicalTrials.gov.